Investorideas.com

Get investor ideas from our AI, cannabis, cleantech, crypto, gaming, mining, sports podcasts - be a guest or sponsor: call 800 665 0411

 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Health Tech Company Acquiring Ontario Health Management Firm, Its Largest Transaction Ever
April 19, 2021 (Investorideas.com Newswire) A Research Capital Corp. report discusses CloudMD Software & Services' acquisition of Oncidium, "one of Canada's leading health management companies."

Ardelyx to Receive $5M Milestone Payment as Japan Partner Initiates Phase 3
April 16, 2021 (Investorideas.com Newswire) Ardelyx Inc. shares traded 11% higher after Kyowa Kirin Co. Ltd., its collaborative partner in Japan, initiated four Phase 3 clinical trials of tenapanor for treatment of hyperphosphatemia.

Novocure Shares Climb 50% on Acceleration of Phase 3 Lung Cancer Trial
April 14, 2021 (Investorideas.com Newswire) Novocure Ltd. shares reached a new 52-week high after the company reported an update from its Phase 3 Pivotal LUNAR trial of tumor treating electrical fields in non-small cell lung cancer.

Gene Therapy Restoring Light Sensitivity 'Showed Impressive Dose-Response Improvements'
April 8, 2021 (Investorideas.com Newswire) Roth Capital Partners advised that Applied Genetic Technologies co-development of BS01 with Bionic Sight "validates its gene therapy capabilities."

Biohaven Expects Net Revenue of $43.8 Million in Q1 for Its Migraine Medicine
April 8, 2021 (Investorideas.com Newswire) Biohaven Pharmaceutical shares traded 10% higher after the company reported that in Q1/21 net product revenue for its migraine drug NURTEC ODT is estimated to be approximately $43.8 million.

Biopharma's Phase 2b/3 Alzheimer's Disease Trial Approved to Continue
April 8, 2021 (Investorideas.com Newswire) Anavex Life Sciences' study, its drug's mechanism of action and the company's upcoming catalysts are covered in a Dawson James Securities report.

Nano-X Imaging Receives Go Ahead from FDA for Single Source Digital X-Ray
April 6, 2021 (Investorideas.com Newswire) Shares of Nano-X Imaging Ltd. traded 17% higher after the company reported that the FDA has granted 510(k) approval for its single source ARC digital x-ray.

ProQR Shares Gain 62% on Stellar Results in Phase 1/2 Usher Syndrome Trial
March 26, 2021 (Investorideas.com Newswire) ProQR Therapeutics shares reached a new 52-week high after the company reported highly positive results from its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.

Aptose Biosciences Shares Rise 55% on Q4 Financial Results and Promising Clinical Trials
March 25, 2021 (Investorideas.com Newswire) Aptose Biosciences Inc. shares traded 55% higher after the company posted Q4 and FY/20 financial results and provided an update on the status of its drug candidates in ongoing clinical trials investigating treatments for life threatening hematologic cancers.

Biopharma to Request U.S. Emergency Use Authorization for COVID-19 Vaccine in April
March 25, 2021 (Investorideas.com Newswire) Catalysts expected in 2021-2022 regarding Ocugen's pipeline therapeutics are discussed in a ROTH Capital Partners report.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Related Guest Posts

Buy a guest post on Investorideas.com

Biotech News from Newsfile

ScreenPro Announces Application for US Listing on OTCQB Venture Market and Electronic Clearing with Depository Trust & Clearing Corp.
Toronto, Ontario--(Newsfile Corp. - April 21, 2021) - ScreenPro Security Inc. (CSE: SCRN) ("ScreenPro" or the "Company") is pleased to announce that it has applied to the OTC Markets Group to trade on the OTCQB Venture Market ("OTCQB"), a US trading platform operated by the OTC Markets Group in New York. The Company believes that trading on the OTCQB will provide increase its visibility for ScreenPro and additional liquidity within the U.S. capital markets....

Universal PropTech Inc. Now Listed on the OTCQB Under the Symbol "UPIPF"
Toronto, Ontario--(Newsfile Corp. - April 21, 2021) - Universal PropTech Inc. (TSXV: UPI) (FSE:8LH) ("UPI" or the "Company") is pleased to announce that it has received approval and will begin trading on the OTCQB, a U.S. market operated by OTC Markets Group Inc. ("OTC") in New York. The Company's shares will begin trading on the OTCQB on April 21, 2021, under the symbol "UPIPF".Chris Hazelton, CEO of Universal PropTech commented: "We are excited to...

Nextleaf Solutions Onboards New Partner and Delivers Initial Bulk CBD Order
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2021) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company") , the world's most innovative cannabis processor, is pleased to announce that its wholly-owned subsidiary Nextleaf Labs Ltd. ("Nextleaf Labs" or "Labs") has completed an inaugural bulk CBD distillate delivery to a U.S.-listed, Canadian-based global cannabis company. The Company anticipates similar orders on an ongoing basis.Cannot view this video? Visit:https://www.youtube.com/watch?v=SCVOJPYFDAIWhile the...

CVR Medical Corp.: Message from the Chief Executive Officer
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2021) - CVR Medical Corp (TSXV: CVM) (OTC Pink: CRRVF) ("CVR Medical" or the "Company" or "we"), a Canadian listed and US-based healthcare company in the medical device market is pleased to share a message from Chief Executive Officer (CEO) Michael Rhodes.After several weeks of negotiation, I am delighted that we have succeeded in agreeing with CVR Global Inc. an amended restructuring agreement. My previous message outlined...

BioMark Announces Exercise of Warrants and Gain DTC Eligibility for Its Common Shares
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2021) -  BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today the agreement by several long-time strategic accredited investors and insiders to exercise approximately 2,000,000 warrants issued in connection with the Company's private placement of units completed in April 2019, with the warrant exercise price of $0.20 per share. All the warrants were exercised before the warranty maturity date of...

Subscribe to Biotech News